# Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

> **NCT04048876** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 56 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease
- Liver Cirrhosis

## Interventions

- **DRUG:** CC-90001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04048876
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-14
- **Primary completion:** 2021-09-28
- **Final completion:** 2021-09-28
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04048876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04048876, "Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04048876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*